Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2012. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility (PDMRs), and connected persons regarding their holdings in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction details rather than financial performance metrics.
Material Changes
The filing details an increase in share interests for specific individuals following the re-investment of dividends paid on October 4, 2012. The transactions occurred at a price of 1,460.962 pence per Ordinary Share. Specific increases include:
- Sir Andrew Witty: 2,150 shares
- Lady C Witty: 1,628 shares
- Dr D Pulman: 341 shares
- Mrs C R Pulman: 69 shares
- Mr I W Whyte: 99 shares
- Mrs V A Whyte: No increase reported
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is a regulatory disclosure of insider trading activity compliant with Disclosure and Transparency Rules 3.1.4R(1)(a) and (c).
Key Facts for Investor Verification
- Verify the dividend reinvestment price of 1,460.962 pence per share against market data for October 4, 2012.
- Confirm the total shareholding positions of the named directors and connected persons post-transaction.
- Note that this filing contains no operational or financial performance data for the period.